are glp 1 compounds going away Compound versions of GLP-1 drugs for weight loss halted by FDA The GLP-1 boom: Challenges, trends,

Some patients notice appetite changes early

Microdosing on GLP-1: benefits and scientific evidence

Rare side effects include pancreatitis, acute kidney injury, worsening diabetes-related retinopathy and medullary thyroid cancer

The Provider's Role in Securing Medicaid Coverage Healthcare providers play a crucial role in determining whether their patients can access weight loss medications through Medicaid

Available from Accessed 23 July 2024 Ethics declarations Data availability The datasets presented in this article are not readily available due to legal restrictions on sharing the dataset as regulated by the Valencia regional government by means of legal resolution by the Valencia Health Agency [2009/13312] which forbids the dissemination of data to third parties (accessible at: Upon request, authors can allow access to the databases to verify the accuracy of the analysis or the reproducibility of the study

Clinical trials show that higher doses of semaglutide and tirzepatide produce greater weight loss